A drug dubbed the ‘Trojan horse’ of cancer treatments has shown promise in patients with different tumor types.
Among patients at the advanced, drug-resistant stage of the disease, more than a quarter with cervical and bladder tumors, and nearly 15% with ovarian and lung cancer, responded to the new treatment.
Called tisotumab vedotin (TV), the drug is being developed by biotech companies Genmab (OMX: GEN) and Seattle Genetics (Nasdaq: SGEN) in partnership with The Institute of Cancer Research, London.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze